STOCK TITAN
  1. Home
  2. Sec-filings
  3. KPTI
  4. [Form 4] Karyopharm Therapeutics Inc. Insider Trading Activity

Karyopharm (KPTI) director awarded 15,508 RSUs vesting in 2027

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. director Deepika Pakianathan received an equity award in the form of 15,508 restricted stock units, which convert into common stock on a one-for-one basis. The RSUs vest in full on May 21, 2027, with share delivery deferred until separation from service or a change-in-control event.

Positive

  • None.

Negative

  • None.
Insider PAKIANATHAN DEEPIKA
Role null
Type Security Shares Price Value
Grant/Award Common Stock 15,508 $0.00 --
Holdings After Transaction: Common Stock — 15,508 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 15,508 units Restricted stock unit award to director on May 21, 2026
Grant price $0.0000 per unit Compensation grant, not open-market purchase
Post-grant holdings 15,508 shares/RSUs Total shown following transaction
Vesting date May 21, 2027 RSUs vest 100% on this date
restricted stock units ("RSUs") financial
"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2022 Equity Incentive Plan financial
"pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended"
change-in-control event financial
"delivery of the shares is deferred until the earlier of ... and (b) a change-in-control event"
separation from service financial
"until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PAKIANATHAN DEEPIKA
(Last)(First)(Middle)
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVE
(Street)
NEWTON MASSACHUSETTS 02459
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/21/2026A15,508(1)A$015,508D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
/s/ Nancy Smith, Attorney-in-Fact for Deepika Pakianathan05/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Karyopharm (KPTI) director Deepika Pakianathan receive in this Form 4?

Director Deepika Pakianathan received an award of 15,508 restricted stock units. These RSUs were granted under Karyopharm’s 2022 Equity Incentive Plan and represent a form of stock-based compensation that converts into common shares on a one-for-one basis when delivered.

When do the 15,508 Karyopharm (KPTI) RSUs vest for Deepika Pakianathan?

The 15,508 restricted stock units vest 100% on May 21, 2027. Vesting means the award is earned, though the actual delivery of common shares occurs later, tied to separation from service or a change-in-control event, whichever happens first.

At what price were Deepika Pakianathan’s Karyopharm (KPTI) RSUs granted?

The RSU award is shown with a transaction price per share of $0.0000 because it is a compensation grant, not a market purchase. RSUs typically carry no exercise price; they convert into common stock based on service or performance conditions once vested.

How many Karyopharm (KPTI) shares does Deepika Pakianathan hold after this RSU grant?

Following the RSU grant, the Form 4 shows 15,508 shares associated with this award. These RSUs convert into common stock on a one-for-one basis, but share delivery occurs only upon separation from service or a qualifying change-in-control event, per the plan terms.

What plan governs Deepika Pakianathan’s Karyopharm (KPTI) RSU award?

The award was granted under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan authorizes stock-based compensation such as restricted stock units, which help align director and employee interests with long-term shareholder value through equity ownership.